Abstract:This study aimed to evaluate the feasibility of defining an in vivo dosimetry (IVD) protocol as a patient-specific quality assurance (PSQA) using the bead thermoluminescent dosimeters (TLDs) for point and 3D IVD during brachytherapy (BT) of gynecological (GYN) cancer using 60 Co high-dose-rate (HDR) source. Methods: The 3D in vivo absorbed dose verification within the rectum and bladder as organs-at-risk was performed by bead TLDs for 30 GYN cancer patients. For rectal wall dosimetry, 80 TLDs were placed in ax… Show more
“…An alternative approach for personalised dosimetry could be the use of micro-sized thermoluminescent dosimeters (TLD). This has been applied with some success to EBRT and brachytherapy where the detectors are placed on the skin, in body activities or behind the patient (41)(42)(43). Since there is limited research being done on their applicability in RLT, it is assumed that TLDs will have to be implanted into the tumour tissue to have accurate measurements.…”
Section: Current Clinical Practice Of Rlt Dosimetry and Its Shortcomingsmentioning
Personalised dosimetry based on molecular imaging is a field that grew exponentially in the last decade due to the increasing success of Radioligand Therapy (RLT). Despite advances in image-based 3D dose estimations, the administered dose of a therapeutic radiopharmaceutical for RLT is often non-personalized, with standardised dose regimes administered every 4–6 weeks. Biodosimetry markers, such as chromosomal aberrations, could be used alongside image-based dosimetry as a tool for individualised dose estimations to further understand normal tissue toxicity and refine the administered dose. In this review we give an overview of biodosimetry markers that are used for blood dose estimations, followed by an overview of their current results when applied in RLT patients. Finally, an in-depth discussion will give a perspective on the potential for the use of biodosimetry in the nuclear medicine clinic.
“…An alternative approach for personalised dosimetry could be the use of micro-sized thermoluminescent dosimeters (TLD). This has been applied with some success to EBRT and brachytherapy where the detectors are placed on the skin, in body activities or behind the patient (41)(42)(43). Since there is limited research being done on their applicability in RLT, it is assumed that TLDs will have to be implanted into the tumour tissue to have accurate measurements.…”
Section: Current Clinical Practice Of Rlt Dosimetry and Its Shortcomingsmentioning
Personalised dosimetry based on molecular imaging is a field that grew exponentially in the last decade due to the increasing success of Radioligand Therapy (RLT). Despite advances in image-based 3D dose estimations, the administered dose of a therapeutic radiopharmaceutical for RLT is often non-personalized, with standardised dose regimes administered every 4–6 weeks. Biodosimetry markers, such as chromosomal aberrations, could be used alongside image-based dosimetry as a tool for individualised dose estimations to further understand normal tissue toxicity and refine the administered dose. In this review we give an overview of biodosimetry markers that are used for blood dose estimations, followed by an overview of their current results when applied in RLT patients. Finally, an in-depth discussion will give a perspective on the potential for the use of biodosimetry in the nuclear medicine clinic.
This study aimed to evaluate the feasibility of defining an in vivo dosimetry (IVD) protocol as a patient-specific quality assurance (PSQA) using the bead thermoluminescent dosimeters (TLDs) for point and 3D IVD during brachytherapy (BT) of gynecological (GYN) cancer using 60 Co high-dose-rate (HDR) source. Methods: The 3D in vivo absorbed dose verification within the rectum and bladder as organs-at-risk was performed by bead TLDs for 30 GYN cancer patients. For rectal wall dosimetry, 80 TLDs were placed in axial arrangements around a rectal tube covered with a layer of gel. Ten beads were placed inside the Foley catheter to get the bladder-absorbed dose. Beads TLDs were localized and defined as control points in the treatment planning system (TPS) using CT images of the patients. Patients were planned and treated using the routine BT protocol. The experimentally obtained absorbed dose map of the rectal wall and the point dose of the bladder were compared to the TPSs predicted absorbed dose at these control points. Results: Relative difference between TPS and TLDs results were −8.3% ± 19.5% and −7.2% ± 14.6% (1SD) for rectum-and bladder-absorbed dose, respectively.Gamma analysis was used to compare the calculated with the measured absorbed dose maps. Mean gamma passing rates of 84.1%, 90.8%, and 92.5% using the criteria of 3%/2 mm, 3%/3 mm, and 4%/2 mm were obtained, respectively. Eventually, a "considering level" of at least 85% as pass rate with 4%/2-mm criteria was recommended. Conclusions: A 3D IVD protocol employing bead TLDs was presented to measure absorbed doses delivered to the rectum and bladder during GYN HDR-BT as a reliable PSQA method. 3D rectal absorbed dose measurements were performed. Differences between experimentally measured and planned absorbed dose maps were presented in the form of a gamma index, which may be used as a warning for corrective action.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.